Patents by Inventor Ansgar Wegener

Ansgar Wegener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocycles as kinase inhibitors
    Patent number: 9861635
    Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Merck Patent Gmbh
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Ansgar Wegener, Oliver Poeschke, Michael Busch
  • Triazolo[4,5-d]pyrimidine derivatives
    Patent number: 9855268
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
  • Imidazopyrimidine derivatives
    Patent number: 9617266
    Abstract: Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Ansgar Wegener, Oliver Poeschke, Michael Busch, Jeyaprakashnarayanan Seenisamy
  • Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors
    Patent number: 9416133
    Abstract: Compounds of the formula I in which R1, R2, R, X1, X2, X3, X4, n1, n2, n3 and n4 have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: August 16, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, Christos Tsaklakidis, Birgitta Leuthner, Dirk Wienke, Frank Czauderna, Ansgar Wegener
  • Triazolo[4,5-d]pyrimidine derivatives
    Patent number: 9409914
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 9, 2016
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Kai Schiemann, Ansgar Wegener
  • MACROCYCLES AS KINASE INHIBITORS
    Publication number: 20160166574
    Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: April 9, 2014
    Publication date: June 16, 2016
    Applicant: Merck Patent Gmbh
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Ansgar WEGENER, Oliver POESCHKE, Michael BUSCH
  • Triazolo[4,5-d]pyrimidine derivatives
    Publication number: 20160015712
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 10, 2014
    Publication date: January 21, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Guenter HOELZEMANN, Michel CALDERINI, Ansgar WEGENER, Oliver POESCHKE
  • IMIDAZOPYRIMIDINE DERIVATIVES
    Publication number: 20160002242
    Abstract: Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 7, 2016
    Applicant: Merck Patent GmbH
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Ansgar WEGENER, Oliver POESCHKE, Michael BUSCH, Jeyaprakashnarayanan SEENISAMY
  • HYDROPYRROLOPYRROLE DERIVATIVES FOR USE AS FATTY ACID SYNTHASE INHIBITORS
    Publication number: 20150252046
    Abstract: Compounds of the formula I in which R1, R2, R, X1, X2, X3, X4, n1, n2, n3 and n4 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: August 30, 2013
    Publication date: September 10, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, Christos Tsaklakidis, Birgitta Leuthner, Dirk Wienke, Frank Czauderna, Ansgar Wegener
  • Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity
    Patent number: 9120805
    Abstract: Compounds of the formula I in which R1, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: September 1, 2015
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Hans-Peter Buchstaller, Gerard Moinet, Ansgar Wegener
  • BICYCLIC PYRAZINONE DERIVATIVES
    Publication number: 20150057264
    Abstract: Compounds of the formula I in which R1, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 26, 2015
    Applicant: Merck Patent GmbH
    Inventors: Dieter Dorsch, Hans-Peter Buchstaller, Gerard Moinet, Ansgar Wegener
  • TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20150051202
    Abstract: Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 14, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Kai Schiemann, Carl Deutsch, Guenter Hoelzemann, Daniel Kuhn, Ansgar Wegener, Dominique Swinnen, Horacio Comas
  • TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
    Publication number: 20140378431
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Kai Schiemann, Ansgar Wegener
  • Phosphoamidase assay
    Patent number: 7348160
    Abstract: The present invention relates to the use of compounds and to methods for the qualitative and/or quantitative determination of the activity of phosphoamidases or protein phosphoamidases specific for hydrolyzing phosphoamide (P—N) bonds N-phosphorylated basic amino acids like phospholysine, phosphoarginine and phosphohistidine.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck Patent GmbH
    Inventors: Roland Kellner, Ansgar Wegener
  • Phosphoamidase assay
    Publication number: 20050124023
    Abstract: The present invention relates to the use of compounds and to methods for the qualitative and/or quantitative determination of the activity of phosphoamidases or protein phosphoamidases specific for hydrolyzing phosphoamide (P—N) bonds. N-phosphorylated basic amino acids like phospholysine, phosphoarginine and phosphohistidine.
    Type: Application
    Filed: October 10, 2003
    Publication date: June 9, 2005
    Inventors: Roland Kellner, Ansgar Wegener